Title:
Operating Grant:Bringing Rare Disease Gene Therapies to Clinical Trial Readiness
Agreement Value:
$1,137,500.00
Agreement Date:
Apr 1, 2024 - Mar 31, 2028
Description:
The specific objectives of this funding opportunity are to:
• Increase and advance the development of gene therapies for rare disease clinical trials in Canada;
• Generate the evidence required for first-in-human clinical trials, in part by working with Canada’s biomanufacturing capacity (National Research Council of Canada) and health technology regulator (Health Canada); and,
• Increase current and future capacity across the Canadian rare disease landscape (i.e., among researchers, knowledge users, patient(s)/caregiver(s)/family) to improve readiness of gene therapies for first-in-human clinical trials.
Organization:
Canadian Institutes of Health Research
Expected Results:
This program provides funding for targeted grants and awards aimed at addressing priority areas. Priorities are identified by CIHR in consultation with other government departments and agencies, partners and stakeholders. The program mobilizes researchers, patients, health providers, and decision makers to conduct research, enable knowledge translation and build capacity in the priority areas. It often requires collaboration within and across sectors.
Location:
Montreal, Quebec, CA H3G 1A4
Reference Number:
236-2024-2025-Q1-00982
Report Type:
Grants and Contributions
Recipient Type:
Individual or sole proprietorship
Recipient's Legal Name:
Braverman, Nancy E
Research Organization:
Research Institute of the McGill University Health Centre|Institut de recherche du Centre universitaire de santé McGill
Program:
Research in Priority Areas
Program Purpose:
This program provides funding for targeted grants and awards aimed at addressing priority areas. Priorities are identified by CIHR in consultation with other government departments and agencies, partners and stakeholders. The program mobilizes researchers, patients, health providers, and decision makers to conduct research, enable knowledge translation and build capacity in the priority areas. It often requires collaboration within and across sectors.